VirionHealth raises series A round

U.K.-based VirionHealth Ltd. said it raised "up to £13 million" ($17.1 million) in a series A round from Abingworth. The company is developing defective interfering virus particles that can treat a range of infectious diseases. CEO Nicola Thompson declined to give specific financial terms.

Thompson told BioCentury the funds will take the virtual company through first-in-man trials for its lead candidate, which is in preclinical development to treat respiratory syncytial virus (RSV) and influenza infections...